Core/shell particles and capsules formed by a layer-by-layer technique are biofunctionalized with a humanized A33 monoclonal antibody (huA33 mAb) that binds to the A33 antigen present on colorectal cancer cells (see figure). Targeting to a colorectal cancer cell line shows selective binding and internalization of particles.